Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside
Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therape...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (296 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993545299204498 |
|---|---|
| ctrlnum |
(CKB)5690000000011929 (oapen)https://directory.doabooks.org/handle/20.500.12854/87543 (EXLCZ)995690000000011929 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Tagit, Oya edt Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (296 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations. English Technology: general issues bicssc History of engineering & technology bicssc Materials science bicssc poly(lactic-co-glycolic acid) (PLGA) blood–brain barrier (BBB) current Good Manufacturing Practice (cGMP) Food and Drug Administration (FDA) nanotechnology PLGA nanoparticles neurodegenerative diseases drug delivery central nervous system neuroprotective drugs fluorescent labeling DiI coumarin 6 rhodamine 123 Cy5.5 quantum yield brightness stability of fluorescent label confocal microscopy intracellular internalization in vivo neuroimaging double-emulsion method dry powder inhalation antigen release porous PLGA particles microfluidics methotrexate chitosan PLA/PLGA sustained release micro-implant animal model minimally invasive drug delivery system nanoparticles poly (lactic-co-glycolic acid) (PLGA) microfluidic pharmacokinetics (PK) and biodistribution atorvastatin calcium poly(lactide-co-glycolide) polymeric nanoparticles carrageenan induced inflammation anti-inflammatory radiolabeled nanoparticles nuclear medicine photothermal therapy phthalocyanine SKOVip-kat Katushka TurboFP635 JO-4 PLGA orthotopic tumors 3D culture spheroids poly(lactic-co-glycolic acid) nanomedicine scale-up manufacturing clinical translation inline sonication tangential flow filtration lyophilization downstream processing H. pylori design of experiments poly(lactic-co-glycolic) acid size cancer chemoimmunotherapy immunogenic cell death immune checkpoint blockade PNA5 glycopeptide mas receptor angiotensin PLGA diblock copolymer ester and acid-end capped double emulsion solvent evaporation biocompatible biodegradable cardiovascular nanoparticle solid-state characterization in vitro drug release kinetics modeling PEGylation amine emulsion polyvinyl alcohol (PVA) Pluronic triblock copolymer trehalose sucrose Indomethacin solvents stabilizers morphology particle-size encapsulation drug release cytotoxicity 3-0365-4490-9 3-0365-4489-5 Tagit, Oya oth |
| language |
English |
| format |
eBook |
| author2 |
Tagit, Oya |
| author_facet |
Tagit, Oya |
| author2_variant |
o t ot |
| author2_role |
Sonstige |
| title |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| spellingShingle |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| title_full |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| title_fullStr |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| title_full_unstemmed |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| title_auth |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| title_alt |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease |
| title_new |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| title_sort |
nanomedicine formulations based on plga nanoparticles for diagnosis, monitoring and treatment of disease: from bench to bedside |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2022 |
| physical |
1 electronic resource (296 p.) |
| isbn |
3-0365-4490-9 3-0365-4489-5 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT tagitoya nanomedicineformulationsbasedonplgananoparticlesfordiagnosismonitoringandtreatmentofdiseasefrombenchtobedside AT tagitoya nanomedicineformulationsbasedonplgananoparticlesfordiagnosismonitoringandtreatmentofdisease |
| status_str |
n |
| ids_txt_mv |
(CKB)5690000000011929 (oapen)https://directory.doabooks.org/handle/20.500.12854/87543 (EXLCZ)995690000000011929 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1787548485435785216 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05948nam-a2201513z--4500</leader><controlfield tag="001">993545299204498</controlfield><controlfield tag="005">20231214133001.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202207s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5690000000011929</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/87543</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995690000000011929</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tagit, Oya</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (296 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Technology: general issues</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">History of engineering & technology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Materials science</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly(lactic-co-glycolic acid) (PLGA)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood–brain barrier (BBB)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">current Good Manufacturing Practice (cGMP)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Food and Drug Administration (FDA)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanotechnology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLGA nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurodegenerative diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">central nervous system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuroprotective drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluorescent labeling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DiI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coumarin 6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rhodamine 123</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cy5.5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quantum yield</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brightness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stability of fluorescent label</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">confocal microscopy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intracellular internalization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo neuroimaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">double-emulsion method</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dry powder inhalation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen release</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">porous PLGA particles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microfluidics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methotrexate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chitosan</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLA/PLGA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sustained release</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">micro-implant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">minimally invasive</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly (lactic-co-glycolic acid) (PLGA)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microfluidic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacokinetics (PK) and biodistribution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">atorvastatin calcium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly(lactide-co-glycolide)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polymeric nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carrageenan induced inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-inflammatory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiolabeled nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">photothermal therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phthalocyanine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SKOVip-kat</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Katushka</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TurboFP635</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">JO-4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLGA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">orthotopic tumors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3D culture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">spheroids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly(lactic-co-glycolic acid)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanomedicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">scale-up manufacturing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical translation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inline sonication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tangential flow filtration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lyophilization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">downstream processing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">H. pylori</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">design of experiments</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">poly(lactic-co-glycolic) acid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">size</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemoimmunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenic cell death</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint blockade</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PNA5 glycopeptide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mas receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">angiotensin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PLGA diblock copolymer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ester and acid-end capped</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">double emulsion solvent evaporation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biocompatible</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biodegradable</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiovascular</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solid-state characterization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug release kinetics modeling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PEGylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">amine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">emulsion</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polyvinyl alcohol (PVA)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pluronic triblock copolymer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">trehalose</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sucrose</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Indomethacin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">solvents</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stabilizers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">morphology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">particle-size</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">encapsulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug release</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytotoxicity</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4490-9</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4489-5</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tagit, Oya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:39:10 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-14 08:50:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337852320004498&Force_direct=true</subfield><subfield code="Z">5337852320004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337852320004498</subfield></datafield></record></collection> |